We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals Inc
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

131 hedge funds and large institutions have $652M invested in Sciclone Pharmaceuticals Inc in 2014 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 47 increasing their positions, 42 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 8

206% more capital invested

Capital invested by funds: $213M → $652M (+$439M)

13% more funds holding

Funds holding: 116131 (+15)

12% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 42

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

35% less call options, than puts

Call options by funds: $608K | Put options by funds: $939K

Holders
131
Holders Change
+15
Holders Change %
+12.93%
% of All Funds
3.49%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
25
Increased
47
Reduced
42
Closed
8
Calls
$608K
Puts
$939K
Net Calls
-$331K
Net Calls Change
-$168K
Name Holding Trade Value Shares
Change
Change in
Stake
Norges Bank
26
Norges Bank
Norway
$2.38M +$1.32M +163,206 +151%
Millennium Management
27
Millennium Management
New York
$2.35M +$832K +102,844 +62%
Connor, Clark & Lunn Investment Management (CC&L)
28
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$2.33M +$151K +18,700 +8%
California Public Employees Retirement System
29
California Public Employees Retirement System
California
$2.33M +$370K +45,700 +17%
SFM
30
Systematic Financial Management
New Jersey
$2.31M +$2.14M +264,025 New
BA
31
BlackRock Advisors
Delaware
$2.14M -$362K -44,711 -15%
PP
32
PDT Partners
New York
$2.03M +$120K +14,800 +7%
GT
33
Glenmede Trust
Pennsylvania
$1.98M +$1.83M +226,280 New
PAAMCP
34
Pacific Alternative Asset Management Company (PAAMCO)
California
$1.85M +$200K +24,728 +13%
TCIM
35
TIAA CREF Investment Management
New York
$1.76M -$98.8K -12,209 -6%
Renaissance Technologies
36
Renaissance Technologies
New York
$1.75M +$919K +113,520 +132%
Two Sigma Investments
37
Two Sigma Investments
New York
$1.67M -$984K -121,557 -39%
Goldman Sachs
38
Goldman Sachs
New York
$1.55M +$760K +93,831 +114%
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$1.51M +$814K +100,571 +139%
CS
40
Credit Suisse
Switzerland
$1.49M +$628K +77,546 +84%
BCM
41
Bridgeway Capital Management
Texas
$1.46M
State Board of Administration of Florida Retirement System
42
State Board of Administration of Florida Retirement System
Florida
$1.45M -$156K -19,296 -10%
SCM
43
Sterling Capital Management
North Carolina
$1.42M -$287K -35,485 -18%
GCP
44
GSA Capital Partners
United Kingdom
$1.41M +$335K +41,363 +34%
Two Sigma Advisers
45
Two Sigma Advisers
New York
$1.41M -$409K -50,500 -24%
BIM
46
BlackRock Investment Management
Delaware
$1.38M -$6.68K -825 -0.5%
GC
47
Globeflex Capital
California
$1.31M +$1.21M +149,733 +37,247%
CCM
48
Cadence Capital Management
Massachusetts
$1.22M -$132K -16,296 -11%
Invesco
49
Invesco
Georgia
$1.21M +$706K +87,278 +171%
TC
50
TFS Capital
Pennsylvania
$1.21M -$575K -70,985 -34%

SCLN Hedge Fund Activity: Q4 2014 in Review

131 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q4 2014, worth a combined $652M — up 206% from $213M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new SCLN positions and 8 closed out — a net gain of 17 holders — while 47 added to existing stakes and 42 trimmed.

The largest buyer was McKinley Capital Management, opening a new position worth an estimated $6.86M. The largest seller was LSV Asset Management, cutting an estimated $4.19M.

  • 131 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q4 2014, up from 116 in Q3 2014.
  • Funds reported $652M of Sciclone Pharmaceuticals Inc stock for Q4 2014, up 206% quarter-over-quarter.
  • 25 funds opened new Sciclone Pharmaceuticals Inc positions in Q4 2014 and 8 closed out, a net change of +17 holders.
  • The largest Sciclone Pharmaceuticals Inc buyer in Q4 2014 was McKinley Capital Management, an estimated $6.86M added.
  • The largest Sciclone Pharmaceuticals Inc seller in Q4 2014 was LSV Asset Management, an estimated $4.19M sold.

Based on aggregated 13F filings for Q4 2014.